Published in Postgrad Med on September 01, 2009
Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med (2007) 10.06
Cisplatin and radiotherapy with or without erlotinib in locally advanced squamous cell carcinoma of the head and neck: a randomized phase II trial. J Clin Oncol (2013) 2.29
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. J Clin Oncol (2006) 1.84
Immunotherapy as a strategy for the treatment of non-small-cell lung cancer. Therapy (2011) 1.74
EGFR targeting of solid tumors. Cancer Control (2007) 1.61
Primary hepatic non-Hodgkin's lymphomas: case report and review of the literature. Am J Gastroenterol (2003) 1.19
A multicenter, phase 2 study of vascular endothelial growth factor trap (Aflibercept) in platinum- and erlotinib-resistant adenocarcinoma of the lung. J Thorac Oncol (2010) 1.16
Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer. J Clin Oncol (2011) 1.04
Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck. Oral Oncol (2012) 0.94
New targets for non-small-cell lung cancer therapy. Expert Rev Anticancer Ther (2007) 0.92
Intensity-modulated radiotherapy with concurrent chemotherapy for previously irradiated, recurrent head and neck cancer. Int J Radiat Oncol Biol Phys (2007) 0.90
Pemetrexed-associated urticarial vasculitis. Lung Cancer (2005) 0.90
The role of proteasome inhibition in nonsmall cell lung cancer. J Biomed Biotechnol (2011) 0.87
Novel molecular targeted therapies for refractory thyroid cancer. Head Neck (2011) 0.87
Efficacy and toxicity of chemoradiotherapy with carboplatin and irinotecan followed by consolidation docetaxel for unresectable stage III non-small cell lung cancer. J Thorac Oncol (2010) 0.86
Heat shock protein-based cancer vaccines. Hematol Oncol Clin North Am (2006) 0.86
Immunotherapeutic agents in non-small-cell lung cancer finally coming to the front lines. Curr Oncol Rep (2014) 0.85
Gene expression profiling and non-small-cell lung cancer: where are we now? Clin Lung Cancer (2009) 0.84
Current results and future applications of radioimmunotherapy management of non-Hodgkin's lymphoma. Leuk Lymphoma (2006) 0.84
Successful treatment of autoimmune hepatitis and idiopathic thrombocytopenic purpura with the monoclonal antibody, rituximab: case report and review of literature. Liver Int (2006) 0.83
EGF receptor in lung cancer: a successful story of targeted therapy. Expert Rev Anticancer Ther (2010) 0.82
Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor. Expert Opin Biol Ther (2013) 0.81
Targeting the Met pathway in lung cancer. Expert Rev Anticancer Ther (2012) 0.81
Targeting angiogenesis from multiple pathways simultaneously: BIBF 1120, an investigational novel triple angiokinase inhibitor. Invest New Drugs (2011) 0.81
BIBF 1120/ nintedanib : a new triple angiokinase inhibitor-directed therapy in patients with non-small cell lung cancer. Expert Opin Investig Drugs (2013) 0.80
Concurrent chemoradiotherapy versus induction chemotherapy followed by chemoradiotherapy (sequential approach) in the management of head and neck cancer. Expert Rev Anticancer Ther (2013) 0.80
Nasopharyngeal carcinoma: alternative treatment options after disease progression. Expert Rev Anticancer Ther (2010) 0.80
Active immunotherapy for non-small-cell lung cancer: moving toward a reality. Expert Rev Anticancer Ther (2011) 0.79
Allogeneic tumor-cell-based vaccines secreting endoplasmic reticulum chaperone gp96. Expert Opin Biol Ther (2007) 0.79
How is gene-expression profiling going to challenge the future management of lung cancer? Future Oncol (2009) 0.79
Entinostat (SNDX-275) for the treatment of non-small cell lung cancer. Expert Opin Investig Drugs (2015) 0.79
Epidermal growth factor vaccine in non-small-cell lung cancer. Expert Rev Anticancer Ther (2012) 0.78
Emerging role of multikinase inhibitors for refractory thyroid cancer. Biologics (2012) 0.78
Second-line therapy for non-small-cell lung cancer. Clin Lung Cancer (2009) 0.77
Erlotinib (tarceva) for the treatment of non-small-cell lung cancer and pancreatic cancer. P T (2009) 0.77
Efficacy of sorafenib, a multi-tyrosine kinase inhibitor, in an adenoid cystic carcinoma metastatic to the lung: case report and review of literature. J Med Case Rep (2011) 0.77
DNA methylation: its role in lung carcinogenesis and therapeutic implications. Expert Rev Anticancer Ther (2005) 0.77
Radiation technique influence on percutaneous endoscopic gastrostomy tube dependence: Comparison between two radiation schemes. Head Neck (2009) 0.76
Irinotecan and docetaxel as first line chemotherapy in patients with stage IIIB/IV non-small cell lung cancer--experience from a prematurely closed phase II study. Lung Cancer (2004) 0.76
Development of targeted therapy for squamous cell carcinomas of the head and neck. Expert Rev Anticancer Ther (2011) 0.75
Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer. J Clin Oncol (2005) 0.75
Accelerated second-line or maintenance chemotherapy versus treatment at disease progression in NSCLC. Expert Rev Anticancer Ther (2010) 0.75
Controversies in the management of stage IIIA non-small-cell lung cancer. Expert Rev Anticancer Ther (2008) 0.75
Induction chemotherapy in the management of squamous cell carcinoma of the head and neck. Expert Rev Anticancer Ther (2006) 0.75
Targeting important pathways in head and neck cancer: from the bench to the clinic. Expert Rev Anticancer Ther (2008) 0.75
Combination of imatinib and cytarabine for the treatment of Philadelphia chromosome positive acute lymphoblastic leukemia. Leuk Lymphoma (2005) 0.75
Cancer vaccines: a new therapeutic alternative for lung cancer therapy? Immunotherapy (2009) 0.75
The utility of a bone marrow biopsy in diagnosing the source of fever of unknown origin in patients with AIDS. J Acquir Immune Defic Syndr (2004) 0.75